Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling
暂无分享,去创建一个
L. Alemany | M. Vilardell | X. Matías-Guiu | M. Carulla | J. Brunet | A. Izquierdo | S. Paytubi | J. Galceran | M. Pineda | R. Marcos-Gragera | L. Costas | R. Clèries | J. Ponce | J. Borras | J. Frias-Gomez | P. Peremiquel-Trillas | J. Martínez | A. Ameijide | J. M. Martínez
[1] M. Parmar,et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2021, The Lancet.
[2] W. Yue,et al. International trends in ovarian cancer incidence from 1973 to 2012 , 2021, Archives of Gynecology and Obstetrics.
[3] M. Pike,et al. Association Between Breastfeeding and Ovarian Cancer Risk. , 2020, JAMA oncology.
[4] F. Bray,et al. The influence of birth cohort and calendar period on global trends in ovarian cancer incidence , 2020, International journal of cancer.
[5] J. Marrugat,et al. Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud , 2019, Revista Española de Cardiología.
[6] J. Marrugat,et al. Excess Weight in Spain: Current Situation, Projections for 2030, and Estimated Direct Extra Cost for the Spanish Health System. , 2019, Revista espanola de cardiologia.
[7] Y. Hao,et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis , 2019, BMC Cancer.
[8] R. Naumann,et al. Ovarian cancer: screening and future directions , 2019, International Journal of Gynecologic Cancer.
[9] A. Gavin,et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.
[10] M. Vilardell,et al. Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly , 2018, Clinical and Translational Oncology.
[11] S. Modesitt,et al. Current and future role of genetic screening in gynecologic malignancies , 2017, American journal of obstetrics and gynecology.
[12] F. Bray,et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype , 2017, International journal of cancer.
[13] A. Green,et al. Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future , 2017, Cancer Causes & Control.
[14] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[15] M. Coleman,et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). , 2017, Gynecologic oncology.
[16] D. Alberts,et al. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials , 2017, Clinical Cancer Research.
[17] C. Navarro,et al. Cancer incidence in Spain, 2015 , 2017, Clinical and Translational Oncology.
[18] C. la Vecchia,et al. Global trends and predictions in ovarian cancer mortality. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] N. Moitt,et al. Cancer incidence and mortality projections in the UK until 2035 , 2016, British Journal of Cancer.
[20] P. A. van den Brandt,et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Crous-Bou,et al. Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. , 2016, American journal of public health.
[22] Yurii B. Shvetsov,et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. , 2016, International journal of epidemiology.
[23] C. Garcés,et al. Earlier menarcheal age in Spanish girls is related with an increase in body mass index between pre‐pubertal school age and adolescence , 2015, Pediatric obesity.
[24] Bernd Holleczek,et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. , 2015, European journal of cancer.
[25] V. Moreno,et al. Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use , 2015, Menopause.
[26] M. Coleman,et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. , 2012, Gynecologic oncology.
[27] A. Al-Niaimi,et al. Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.
[28] C. Navarro,et al. Population-based cancer registries in Spain and their role in cancer control. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] J. Borrás,et al. RiskDiff: a web tool for the analysis of the difference due to risk and demographic factors for incidence or mortality data , 2009, BMC public health.
[30] K. Reynolds,et al. Global burden of obesity in 2005 and projections to 2030 , 2008, International Journal of Obesity.
[31] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[32] J. L. Gutiérrez-Fisac,et al. Increasing prevalence of overweight and obesity among Spanish adults, 1987–1997 , 2000, International Journal of Obesity.
[33] J. Estève,et al. Analysing the difference due to risk and demographic factors for incidence or mortality. , 2000, International journal of epidemiology.
[34] THE WORLD OVARIAN CANCER COALITION ATLAS GLOBAL TRENDS IN INCIDENCE, MORTALITY AND SURVIVAL , 2018 .
[35] I. Shah. Fertility and contraception in Europe: the case of low fertility in southern Europe. , 1997, European journal of contraception & reproductive health care.
[36] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.